Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD Smokers. Academic Article uri icon

Overview

MeSH

  • Adult
  • Biomarkers
  • Case-Control Studies
  • Chromatography, Liquid
  • Cluster Analysis
  • Female
  • Forced Expiratory Volume
  • Healthy Volunteers
  • Humans
  • Male
  • Mass Spectrometry
  • Middle Aged
  • Reproducibility of Results
  • Respiratory Function Tests

MeSH Major

  • Metabolome
  • Metabolomics
  • Pulmonary Disease, Chronic Obstructive
  • Smoking

abstract

  • COPD (chronic obstructive pulmonary disease) is defined by a fixed expiratory airflow obstruction associated with disordered airways and alveolar destruction. COPD is caused by cigarette smoking and is the third greatest cause of mortality in the US. Forced expiratory volume in 1 second (FEV1) is the only validated clinical marker of COPD, but it correlates poorly with clinical features and is not sensitive enough to predict the early onset of disease. Using LC/MS global untargeted metabolite profiling of serum samples from a well-defined cohort of healthy smokers (n = 37), COPD smokers (n = 41) and non-smokers (n = 37), we sought to discover serum metabolic markers with known and/or unknown molecular identities that are associated with early-onset COPD. A total of 1,181 distinct molecular ions were detected in 95% of sera from all study subjects and 23 were found to be differentially-expressed in COPD-smokers vs. healthy-smokers. These 23 putative biomarkers were differentially-correlated with lung function parameters and used to generate a COPD prediction model possessing 87.8% sensitivity and 86.5% specificity. In an independent validation set, this model correctly predicted COPD in 8/10 individuals. These serum biomarkers included myoinositol, glycerophopshoinositol, fumarate, cysteinesulfonic acid, a modified version of fibrinogen peptide B (mFBP), and three doubly-charged peptides with undefined sequence that significantly and positively correlate with mFBP levels. Together, elevated levels of serum mFBP and additional disease-associated biomarkers point to a role for chronic inflammation, thrombosis, and oxidative stress in remodeling of the COPD airways. Serum metabolite biomarkers offer a promising and accessible window for recognition of early-stage COPD.

publication date

  • 2015

has subject area

  • Adult
  • Biomarkers
  • Case-Control Studies
  • Chromatography, Liquid
  • Cluster Analysis
  • Female
  • Forced Expiratory Volume
  • Healthy Volunteers
  • Humans
  • Male
  • Mass Spectrometry
  • Metabolome
  • Metabolomics
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive
  • Reproducibility of Results
  • Respiratory Function Tests
  • Smoking

Research

keywords

  • Journal Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4682670

Digital Object Identifier (DOI)

  • 10.1371/journal.pone.0143937

PubMed ID

  • 26674646

Additional Document Info

start page

  • e0143937

volume

  • 10

number

  • 12